FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592502078> ?p ?o ?g. }

• W2592502078 endingPage "716" @default.
• W2592502078 startingPage "710" @default.
• W2592502078 abstract "Indoleamine 2,3-dioxygenase (IDO), an enzyme for tryptophan metabolism through the kynurenine pathway, exhibits an immunosuppressive effect and induces immune tolerance in tumor cells. The effects of IDO on pancreatic cancer are poorly understood. This study aimed to investigate the expression and prognostic significance of IDO in pancreatic cancer.We evaluated the protein expression of IDO in PANC-1, CFPAC-1, and BxPC-3 cell lines with or without 48 h treatment by 500 U/ml interferon-γ (IFN-γ). We performed immunohistochemical staining and Western blot analysis for IDO expression in both pancreatic cancer and normal pancreas tissues obtained from Chinese PLA General Hospital from July 2012 to December 2013. Survival analysis was performed to correlate IDO expression and histopathologic parameters with overall survival. The Kaplan-Meier method and Cox proportional hazards regression model were conducted.PANC-1, CFPAC-1, and BxPC-3 cell lines expressed IDO at the protein level, and the relative expression amount increased after stimulation with 500 U/ml IFN-γ. Immunohistochemical analysis results revealed that high IDO expression was observed in 59% of pancreatic adenocarcinoma tissues. Compared with normal pancreatic tissues, pancreatic adenocarcinoma showed significantly higher IDO expression levels, especially among patients with high tumor node metastasis (TNM) stages (χ2 = 4.550, P = 0.030), poor histological differentiation (χ2 = 5.690, P = 0.017), and lymph node metastasis (χ2 = 4.340 P = 0.037). Kaplan-Meier survival curves showed that high IDO expression was correlated with low survival rates (hazard ratio [HR] = 0.49 P = 0.009). Multivariate analysis using Cox proportional hazards model indicated that lymph node metastasis (HR = 0.35 P = 0.010) and IDO expression (HR = 0.42 P = 0.020) were two independent prognostic predictors of pancreatic adenocarcinoma.The study confirmed that high IDO expression in pancreatic adenocarcinoma was related to poor prognosis of patients. These findings provided evidence that IDO was involved in pancreatic adenocarcinoma progression and might serve as a relevant therapeutic target." @default.
• W2592502078 created "2017-03-16" @default.
• W2592502078 creator A5018636031 @default.
• W2592502078 creator A5033263569 @default.
• W2592502078 creator A5035701638 @default.
• W2592502078 creator A5059460381 @default.
• W2592502078 creator A5083466095 @default.
• W2592502078 creator A5085618758 @default.
• W2592502078 date "2017-03-20" @default.
• W2592502078 modified "2023-10-17" @default.
• W2592502078 title "Expression and Prognostic Value of Indoleamine 2,3-dioxygenase in Pancreatic Cancer" @default.
• W2592502078 cites W1569673965 @default.
• W2592502078 cites W1790626605 @default.
• W2592502078 cites W1985257726 @default.
• W2592502078 cites W2004528113 @default.
• W2592502078 cites W2007916488 @default.
• W2592502078 cites W2012836981 @default.
• W2592502078 cites W2041467469 @default.
• W2592502078 cites W2057435388 @default.
• W2592502078 cites W2058834701 @default.
• W2592502078 cites W2076232020 @default.
• W2592502078 cites W2079010923 @default.
• W2592502078 cites W2085967747 @default.
• W2592502078 cites W2089265092 @default.
• W2592502078 cites W2107491018 @default.
• W2592502078 cites W2123625916 @default.
• W2592502078 cites W2167758222 @default.
• W2592502078 cites W2179501428 @default.
• W2592502078 cites W2209882029 @default.
• W2592502078 cites W2220882815 @default.
• W2592502078 cites W2235523093 @default.
• W2592502078 cites W2273004055 @default.
• W2592502078 cites W2306053308 @default.
• W2592502078 cites W2306443763 @default.
• W2592502078 cites W2378020047 @default.
• W2592502078 cites W2415782665 @default.
• W2592502078 cites W2423144875 @default.
• W2592502078 cites W2464264982 @default.
• W2592502078 cites W2531826090 @default.
• W2592502078 cites W2553568639 @default.
• W2592502078 cites W2560294214 @default.
• W2592502078 cites W3143082516 @default.
• W2592502078 doi "https://doi.org/10.4103/0366-6999.201613" @default.
• W2592502078 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5358422" @default.
• W2592502078 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28303855" @default.
• W2592502078 hasPublicationYear "2017" @default.
• W2592502078 type Work @default.
• W2592502078 sameAs 2592502078 @default.
• W2592502078 citedByCount "35" @default.
• W2592502078 countsByYear W25925020782018 @default.
• W2592502078 countsByYear W25925020782019 @default.
• W2592502078 countsByYear W25925020782020 @default.
• W2592502078 countsByYear W25925020782021 @default.
• W2592502078 countsByYear W25925020782022 @default.
• W2592502078 countsByYear W25925020782023 @default.
• W2592502078 crossrefType "journal-article" @default.
• W2592502078 hasAuthorship W2592502078A5018636031 @default.
• W2592502078 hasAuthorship W2592502078A5033263569 @default.
• W2592502078 hasAuthorship W2592502078A5035701638 @default.
• W2592502078 hasAuthorship W2592502078A5059460381 @default.
• W2592502078 hasAuthorship W2592502078A5083466095 @default.
• W2592502078 hasAuthorship W2592502078A5085618758 @default.
• W2592502078 hasBestOaLocation W25925020781 @default.
• W2592502078 hasConcept C10515644 @default.
• W2592502078 hasConcept C121608353 @default.
• W2592502078 hasConcept C126322002 @default.
• W2592502078 hasConcept C143998085 @default.
• W2592502078 hasConcept C204232928 @default.
• W2592502078 hasConcept C207103383 @default.
• W2592502078 hasConcept C2776706248 @default.
• W2592502078 hasConcept C2779013556 @default.
• W2592502078 hasConcept C2780210213 @default.
• W2592502078 hasConcept C2781182431 @default.
• W2592502078 hasConcept C44249647 @default.
• W2592502078 hasConcept C502942594 @default.
• W2592502078 hasConcept C50382708 @default.
• W2592502078 hasConcept C515207424 @default.
• W2592502078 hasConcept C55493867 @default.
• W2592502078 hasConcept C71924100 @default.
• W2592502078 hasConcept C83478079 @default.
• W2592502078 hasConcept C86803240 @default.
• W2592502078 hasConceptScore W2592502078C10515644 @default.
• W2592502078 hasConceptScore W2592502078C121608353 @default.
• W2592502078 hasConceptScore W2592502078C126322002 @default.
• W2592502078 hasConceptScore W2592502078C143998085 @default.
• W2592502078 hasConceptScore W2592502078C204232928 @default.
• W2592502078 hasConceptScore W2592502078C207103383 @default.
• W2592502078 hasConceptScore W2592502078C2776706248 @default.
• W2592502078 hasConceptScore W2592502078C2779013556 @default.
• W2592502078 hasConceptScore W2592502078C2780210213 @default.
• W2592502078 hasConceptScore W2592502078C2781182431 @default.
• W2592502078 hasConceptScore W2592502078C44249647 @default.
• W2592502078 hasConceptScore W2592502078C502942594 @default.
• W2592502078 hasConceptScore W2592502078C50382708 @default.
• W2592502078 hasConceptScore W2592502078C515207424 @default.
• W2592502078 hasConceptScore W2592502078C55493867 @default.
• W2592502078 hasConceptScore W2592502078C71924100 @default.
• W2592502078 hasConceptScore W2592502078C83478079 @default.

• next